louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04098133: Epidemiology of Carbapenemase-producing Bacteria in a Swiss Tertiary Care Hospital
Official title: Epidemiology of Carbapenemase-producing Bacteria in a Swiss Tertiary Care Hospital
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Infections With CPB
Keywords: Carbapenemase-producing Klebsiella pneumoniae
antibiotic resistancy
infections with Carbapenemase-producing Bacteria (CPB)
Carbapenemase-producing Bacteria
Lead sponsor: University Hospital, Basel, Switzerland
Sponsor class: OTHER
First posted: 2019-09-23
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: Patients treated in the in- or outpatient setting at the University Hospital Basel with detection of carbapenemase-producing bacteria in any screening or clinical sample from January 1st , 2008 until December 31st , 2028

Brief summary: This retrospective and prospective study is to investigate the incidence of Carbapenemase-producing bacteria (CPB) at the University Hospital Basel, the time to detection of CPB and to initiation of infection control measures, the risk factors associated with carriage of CPB, type and duration of previously administrated antibiotic medication, antibiotic treatment, as well as to assess the outcomes of the affected patients.


Eligibility criteria: Inclusion Criteria:

* Patients with detection of carbapenemase-producing bacteria from January 1st , 2008 until December 31st , 2028

Exclusion Criteria:

* Patients with documented refusal of subsequent use of their data

Primary outcomes:
measure: incidence of CPB at the University Hospital Basel (number)
timeFrame: from January 1st , 2008 until December 31st, 2028
Secondary outcomes:
measure: time to detection of CPB (days)
timeFrame: from January 1st , 2008 until December 31st, 2028
measure: time to initiation of infection control measures
timeFrame: from January 1st , 2008 until December 31st, 2028
measure: time to adequate treatment in patients with CPB infections
timeFrame: from January 1st , 2008 until December 31st, 2028
measure: presence of established risk factors for CPB
timeFrame: from January 1st , 2008 until December 31st, 2028
measure: length of hospital stay (days)
timeFrame: from January 1st , 2008 until December 31st, 2028
measure: discharge destination
timeFrame: from January 1st , 2008 until December 31st, 2028
measure: cure from infection
timeFrame: from January 1st , 2008 until December 31st, 2028
measure: cause-specific mortality (number)
timeFrame: from January 1st , 2008 until December 31st, 2028
measure: all-cause mortality (number)
timeFrame: from January 1st , 2008 until December 31st, 2028
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: Division of Infectious Diseases and Hospital Epidemiology
Study officials:
affiliation: University Hospital Basel, Division of Infectious Diseases and Hospital Epidemiology
name: Sarah Tschudin Sutter, Prof. Dr. MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05256433: Role of Soft Tissue Therapy in Plantar Fasciitis
Official title: Effectiveness of Instrument Assisted Soft Tissue Mobilization (IASTM) And Manual Massage On Thickness, Pain and Foot Function Among Patient With Plantar Fasciitis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: INSTRUMENT ASSISTED SOFT TISSUE MOBILIZATION
Keywords: Musculoskeletal Pain
Myofascial Release
Plantar Fasciitis
Lead sponsor: Ziauddin University
Sponsor class: OTHER
First posted: 2022-02-25
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Plantar Fasciitis (PF) is a frequently and commonly reported heel pain present in every age with multifactorial etiology. It is the most common reason for constant heel pain in adults affecting both young active and older sedentary individuals. PF is reported approx. 11%-15% of all foot symptoms demanding professional care among adults. Instrument-Assisted Soft Tissue Massage (IASTM) refers to a technique that utilizes instruments to eliminate scar tissues and work with mending measure through development of new extracellular lattice proteins like collagen that may be effective in providing immediate and quick pain relief by covering a larger area. On the other hand, numerous options with conservative measures has been frequently documented in treating plantar fasciitis that may include stretching, massage, orthosis, anti-inflammatory agents and surgery etc. Although, transverse friction massage has been considered to be one of the best treatment option in reducing pain, releasing tight areas and promoting flexibility. Besides, several studies reported the usefulness of potential assessment tools for remote monitoring of patients that can be utilized by clinicians for wider range of purposes. To the best of author's knowledge, limited studies has been conducted till date utilizing the IASTM technique in comparison to conservative treatment options with standardized assessments in treating PF. Therefore, this study aims to investigate the effectiveness of IASTM to assess thickness, pain, and foot function by using ultrasound for the management of plantar fasciitis patients. The findings of this study may be useful to establish an effective treatment protocol to enhance the quality of life of the target population.


Eligibility criteria: Inclusion Criteria:

-Pre-diagnosed adults (18-55 years) with plantar fasciitis of both genders.

Exclusion Criteria:

* Pathological bone spurs of the calcaneus
* Burn scars
* Polyneuropathies
* Corticosteroid injections

Primary outcomes:
measure: NPRS
timeFrame: Baseline
measure: NPRS
timeFrame: 4 weeks
measure: FAAM
timeFrame: Baseline
measure: FAAM
timeFrame: 4 weeks
measure: Diagnostic Ultrasound
timeFrame: Baseline
measure: Diagnostic Ultrasound
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Karachi
country: Pakistan
facility: Javeria Mirza
Study officials:
References:
Clinical trial NCT02376933: Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer
Official title: Phase 2 Study of Vertebral Augmentation and Radiotherapy in Painful or at Risk of Collapse Spinal Metastatic Cancer/Multiple Myeloma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Metastatic Cancers
Multiple Myeloma
Vertebral Fracture
Keywords: vertebral bodies
vertebral fracture
vertebral augmentation
radiotherapy
vertebroplasty
kyphoplasty
Lead sponsor: University of Arizona
Sponsor class: OTHER
First posted: 2015-03-03
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Vertebral augmentation with radiotherapy to increase the functional status and quality of life for patients with vertebral body metastatic cancers.

Detailed description: The study quantifies the reduction of pain and changes in quality of life associated with vertebral augmentation. This study is conducted in patients with metastatic cancer or multiple myeloma involving the spine. This study addresses the value of vertebral augmentation in combination with radiotherapy in the setting of cancer to the spine. The patient's pain, overall quality of life, and fracture development/avoidance will be compared to patients treated only with radiotherapy in the past.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of metastatic disease to the vertebra or multiple myeloma
* Negative pregnancy test within 2 weeks prior to registration
* Life expectancy of \>= 3 months and Karnofsky performance status (KPS) score \>= 40
* Pain scale score \>=5
* Pain at involved vertebral body not adequately controlled
* Osteolysis of vertebral bodies
* Must agree to practice adequate means of birth control
* Must sign informed consent prior to study entry
* Must be able to understand the English language
* Absence of any serious cognitive or psychiatric problems potentially hampering compliance with the study and follow-up schedule.

Exclusion Criteria:

* Spinal Cord Compression

Primary outcomes:
measure: Pain Assessment From the Worst Pain Score on Brief Pain Inventory as Compared to Historical Radiation Therapy Oncology Group (RTOG) 9714 Study.
timeFrame: 14 weeks
Secondary outcomes:
measure: Activity Level Assessment From the Roland Morris Questionnaire (RDQ) and Karnofsky Performance Status (KPS)
timeFrame: 14 weeks
measure: Quality of Life Assessment From the EORTC QLQ C30 Questionnaire.
timeFrame: 14 weeks
measure: Fracture Rates Detected From X-rays.
timeFrame: 14 weeks
Other outcomes:
Locations:
city: Tucson
country: United States
facility: University of Arizona
state: Arizona
Study officials:
affiliation: University of Arizona Radiation Oncology
name: Krisha Howell, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06542133: AVEIR Remote Care System Non-Significant Risk Study
Official title: AVEIR Remote Care System Data Collection Non-Significant Risk Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardiac Pacemaker
Cardiac Rhythm Disorder
Bradycardia
Lead sponsor: Abbott Medical Devices
Sponsor class: INDUSTRY
First posted: 2024-08-07
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Primary care clinic

Brief summary: The goal of the study is to understand the performance of the AVEIR Remote Care System in an initial patient cohort which will inform the ability to offer a remote follow-up solution to all patients implanted with Aveir LP devices.

Detailed description: To collect acute performance data about the AVEIR Remote Care System in participants implanted with a compatible dual or single chamber Aveir Leadless Pacemaker System by participants completing remote transmissions with the system

Eligibility criteria: Inclusion Criteria:

* Subject must provide written informed consent prior to any study-related procedure.
* Subject is willing and has consented to study clinical procedure.
* Subject is ≥ 18 years of age or age of legal consent, whichever age is greater
* Subject has an active, appropriately functioning Aveir leadless pacemaker system
* Subject is willing to use the device

Exclusion Criteria:

* Subject is unable to read/write at a sufficient level to provide informed consent.
* Subject is unable to make the decision to participate in a clinical investigation on their own or are unable to fully understand all aspects of the investigation that are relevant to the decision to participate.
* Subject has presence of medical, social, or psychological conditions that, in the investigator's opinion, could confound the study, limit the subject's ability to participate in the clinical investigation .

Primary outcomes:
measure: Successful end-to-end transmission performance metrics
timeFrame: The expected duration of each subject's participation is approximately 30 minutes for an in-clinic visit to complete two transmissions and thereafter an optional at-home transmission (expected duration 10-15 minutes)
Secondary outcomes:
Other outcomes:
Locations:
city: Jonesboro
country: United States
facility: Arrhythmia Research Group
state: Arkansas
city: Little Rock
country: United States
facility: Arkansas Heart Hospital
state: Arkansas
city: Newport Beach
country: United States
facility: Premier Cardiology, Inc
state: California
Study officials:
References:
Clinical trial NCT05950633: Postoperative Active Recovery
Official title: Evaluating a Novel Active Recovery Program in the Immediate Postoperative Period Following Pelvic Reconstructive Surgery: a Randomized Control Trial
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Pelvic Floor Disorders
Lead sponsor: Oregon Health and Science University
Sponsor class: OTHER
First posted: 2023-07-18
Enrollment: 72
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 89
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a study evaluating a novel active recovery program in the immediate postoperative period following pelvic reconstructive surgery.

Detailed description: This is a randomized controlled trial comparing usual care postoperative restrictions and a novel new active recovery program to look at differences in pelvic floor function, patient quality of life, and mental health in between groups.

Eligibility criteria: Inclusion Criteria:

1. Between the ages of 18 and 89
2. Undergoing minimally invasive apical prolapse reconstructive procedure at OHSU. This includes laparoscopic and robotic-assisted sacrocolpopexy, laparoscopic and vaginal uterosacral ligament suspension, and vaginal sacrospinous ligament fixation. We will include patients undergoing concomitant procedures such as hysterectomy and incontinence procedures.
3. Have access to reliable email for communication and questionnaires.

Exclusion Criteria:

1. Unable to consent
2. Unable to read and complete questionnaires in English
3. Unable to sustain 30 minutes of moderate walking/activity at baseline (self-reported)
4. Use a mobility assistance device such as a walker/cane at baseline
5. Balance or stability problems
6. Patients on chronic opioids

Primary outcomes:
measure: Change in the Pelvic Floor Distress Inventory-20 (PFDI-20)
timeFrame: Baseline to 12 weeks post-surgery
measure: Change in the Short Form Health Survey (SF-36)
timeFrame: Baseline to 12 weeks
measure: Change in the Patient Health Questionnaire (PHQ-9)
timeFrame: Baseline to 12 weeks post-surgery
measure: Change in the Patient Global Impression of Improvement (PGI-I)
timeFrame: Baseline to 12 weeks post-surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Portland
country: United States
facility: OHSU
state: Oregon
Study officials:
affiliation: Oregon Health and Science University
name: Sara Cichowski, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05158933: Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Ovarian Failure
Official title: Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Ovarian Failure
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Ovarian Failure
Keywords: Ovarian Failure
stem cell treatment
Lead sponsor: The Foundation for Orthopaedics and Regenerative Medicine
Sponsor class: OTHER
First posted: 2021-12-15
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Ovarian Failure

Detailed description: This patient funded trial aims to study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells (UC-MSCs) for the treatment of Ovarian Failure. Patients will receive a single intravenous infusion of UC-MSCs as well as a transvaginal ultrasound guided injection of UC-MSCs into the Ovarian Niche, with sedation if needed. The total dose will be approximately 1 million cells per kilogram for the intravenous infusion and 25 million cells injected into the Ovarian Niche. Patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy.

For patients with more severe disease an autologous Effector cells (activated lymphocytes) treatment will be utilized created from the patient's own cells obtained by apheresis.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of Ovarian Failure
* Understanding and willingness to sign a written informed consent document

Exclusion Criteria:

* Active infection
* Active cancer
* Chronic multisystem organ failure
* Pregnancy
* Clinically significant Abnormalities on pre-treatment laboratory evaluation
* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.
* Continued drug abuse
* Previous organ transplant
* Hypersensitivity to sulfur

Primary outcomes:
measure: Safety (adverse events)
timeFrame: Four year follow-up
Secondary outcomes:
Other outcomes:
Locations:
city: St. John's
country: Antigua and Barbuda
facility: Medical Surgical Associates Center
Study officials:
affiliation: The Foundation for Orthopaedics and Regenerative Medicine
name: Chadwick Prodromos, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03012633: Rapid Diagnostic of Hyperfibrinolysis in Liver Transplantation
Official title: Rapid Diagnostic of Hyperfibrinolysis in Liver Transplantation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Liver Transplantation
Keywords: hyperfibrinolysis, Lysis Timer
Lead sponsor: University Hospital, Bordeaux
Sponsor class: OTHER
First posted: 2017-01-06
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: adult patients benefiting from liver transplantation

Brief summary: During liver transplantation (LT), hyperfibrinolysis is one of the most important modification of haemostasis. It is associated with t-PA and protein C increased activity. Hyperfibrinolysis is frequent, hardly predictable and associated with major bleeding. The diagnostic of hyperfibrinolysis with standard laboratory tests (euglobulin lysis test, t-PA, PAI-1 and D-dimers dosages) does not provide an answer in a delay compatible with the clinical practice in the operating room.

The "Lysis Timer" is a device developed by Hyphen-Sysmex in collaboration with SD Innovation and Charleroi University Hospital (Belgium). It allows the implementation of the "Global Fibrinolytic Capacity", or GFC test, in a complete system associating i) the reagents for in vitro triggering of the clot and its lysis (contact system activators, t-PA, thrombin and calcium), ii) the signal acquisition by the Lysis Timer (able to convert the analogic signal of the absorbance modifications related to clot formation into a numeric signal) and iii) a dedicated software treating the numeric signal to define clot lysis time.

The GFC test, using t-PA to shorten signal acquisition times, is particularly adapted to the diagnosis of hyperfibrinolysis with PAI-1 collapse, of which LT is an example.

Detailed description: The primary aim of this prospective, monocentric, observational study is to evaluate the Lysis Timer as a rapid diagnostic device for hyperfibrinolysis during liver transplantation. Lysis times provided by this device will be compared to the euglobulin lysis times and to the others parameters of fibrinolysis at the different stages of liver transplantation and more specifically at the anhepatic stage and after graft revascularization.

The secondary aims are to compare the results of the Lysis Timer, the thromboelastogram, the thrombin generation test and the standard laboratory tests in the context of hyperfibrinolysis during liver transplantation.

Eligibility criteria: Inclusion Criteria:

* adult patients benefiting from liver transplantation

Exclusion Criteria:

* age under eighteen

Primary outcomes:
measure: clot lysis time
timeFrame: during the liver transplantation surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Pessac
country: France
facility: BORDEAUX UNIVERSITY HOSPITAL Haut Lévêque
Study officials:
affiliation: head of anesthesia department II
name: Alexandre OUATTARA, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06752733: Cardiac Stunning After Electrical Cardioversion
Official title: The Association Between Myocardial Stunning and Long-term Prognosis After Electrical Cardioversion in Patients with Atrial Fibrillation
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Atrial Fibrillation (AF)
Lead sponsor: Korea University Guro Hospital
Sponsor class: OTHER
First posted: 2024-12-31
Enrollment: 160
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Korea University College of Medicine, Guro Hospital

Brief summary: The goal of this observational study is to evaluate cardiac stunning and electrocardiographic parameters through transthoracic echocardiography and 24 hours ECG conducted immediately following electrical cardioversion. The main question it aims to answer is:

Do echocardiographic and electrocardiographic parameters relating to cardiac stunning predict atrial fibrillation (AF) recurrence rates after electrical cardioversion?

Participants will undergo echocardiography and a 24-hour Holter monitoring immediately after electrical cardioversion.


Eligibility criteria: Inclusion Criteria:

* Patients with atrial fibrillation
* Patients with persistent or symptomatic atrial fibrillation who are candidates for electrical cardioversion
* Patients eligible for anticoagulation therapy for thromboembolism prevention before and after the procedure
* Patients who can understand and provide written informed consent

Exclusion Criteria:

* Patients under 18 years of age or over 80 years of age
* Patients who do not consent to participate in the study
* Patients with severe coronary artery stenosis
* Patients with severe hepatic dysfunction
* Patients with severe renal dysfunction
* Patients with severe valvular heart disease
* Patients with a high risk of severe bleeding
* Patients with a history of atrial fibrillation-related catheter ablation or cardiac surgery
* Patients with an expected life expectancy of less than 1 year
* Potentially pregnant individuals
* Patients deemed unsuitable for the study by the investigator

Primary outcomes:
measure: The recurrence of atrial arrhythmia
timeFrame: From enrollment to the end of treatment at 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Korea University Medicine Guro hospital
Study officials:
References: